help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online August 13, 2008
The Oncologist, Vol. 13, No. 8, 859-875, August 2008; doi:10.1634/theoncologist.2008-0097
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Right arrow All Versions of this Article:
theoncologist.2008-0097v1
13/8/859    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Smits, E. L. J. M.
Right arrow Articles by Van Tendeloo, V. F. I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smits, E. L. J. M.
Right arrow Articles by Van Tendeloo, V. F. I.

Clinical Pharmacology

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

Evelien L. J. M. Smitsa, Peter Ponsaertsa, Zwi N. Bernemana,b, Viggo F. I. Van Tendelooa,b

aVaccine & Infectious Disease Institute (VIDI), Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium; bCenter for Cellular Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium

Key Words. TLR7 • TLR8 • TLR ligands • Cancer • Immunotherapy • Vaccine adjuvant

Correspondence: V. F. I. Van Tendeloo, Ph.D., VIDI, Laboratory of Experimental Hematology, University of Antwerp (UA), Antwerp University Hospital (UZA), Wilrijkstraat 10, B-2650 Antwerp, Belgium. Telephone 32-3-8213661; Fax: 32-3-8214456; e-mail: viggo.van.tendeloo{at}uza.be

Received April 16, 2008; accepted for publication July 14, 2008; first published online in THE ONCOLOGIST Express on August 13, 2008.

Disclosure: The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers.

The importance of Toll-like receptors (TLRs) in stimulating innate and adaptive immunity is now well established. In view of this, TLR ligands have become interesting targets to use as stand-alone immunotherapeutics or vaccine adjuvants for cancer treatment. TLR7 and TLR8 were found to be closely related, sharing their intracellular endosomal location, as well as their ligands.

In this review, we describe the agonists of TLR7 and TLR8 that are known so far, as well as their contribution to antitumor responses by affecting immune cells, tumor cells, and the tumor microenvironment. The major benefit of TLR7/8 agonists as immune response enhancers is their simultaneous stimulation of several cell types, resulting in a mix of activated immune cells, cytokines and chemokines at the tumor site. We discuss the studies that used TLR7/8 agonists as stand-alone immunotherapeutics or cancer vaccine adjuvants, as well as the potential of TLR7/8 ligands to enhance antitumor responses in passive immunotherapy approaches.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2008 by AlphaMed Press.